Charles River Laboratories (CRL) Tops Q4 EPS by 6c; Guides FY16 EPS Above Consensus Midpoint
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $185.00 +1.46%
Revenue Growth %: -5.1%
Financial Fact:
Net income: 38.03M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: -5.1%
Financial Fact:
Net income: 38.03M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $1.00, $0.06 better than the analyst estimate of $0.94. Revenue for the quarter came in at $353.9 million versus the consensus estimate of $349.2 million.
GUIDANCE:
2016 GUIDANCE EXCLUDING WIL RESEARCH | |||
(from continuing operations) | |||
| Revenue growth, reported | 8% - 10% | ||
| Negative impact of foreign exchange | (~1%) | ||
| Revenue growth, constant currency | 9% - 11% |
Charles River Laboratories sees FY2016 EPS of $4.07-$4.17, versus the consensus of $4.16.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Upgrades Charles River Labs (CRL) to Overweight, 'strong uptick in biopharma funding beginning to transition into RFPs and bookings'
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
- SanDisk and Micron surge as Apple confirms memory price pass-through
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
